{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T19:07:51Z","timestamp":1772392071380,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,1,30]],"date-time":"2007-01-30T00:00:00Z","timestamp":1170115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2007,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The effect of the barbiturate T2000 (1,3\u2010dimethoxymethyl\u20105,5\u2010diphenyl\u2010barbituric acid; DMMDPB) on essential tremor, given in twice daily doses of 400 and 300 mg, was assessed in two brief, randomized, placebo\u2010controlled, parallel\u2010group, double\u2010blinded, single\u2010center trials in 12 and 22 patients, respectively. These trials represent the first clinical use of T2000 for a specific indication. The primary endpoint was the change in the mean scores of the treated and control groups based on the Fahn\u2010Tolosa\u2010Marin tremor scale. In the first study of 12 patients treated with 400 mg or placebo twice daily for 14 days, the mean change from baseline at day 14 was 19.3 (<jats:italic>P<\/jats:italic> &lt; 0.0001) in the treated group and 9.0 (<jats:italic>P<\/jats:italic> = 0.0121) in the control group. Using a two\u2010factor mixed ANOVA model to evaluate within group and between group changes, the effect of T2000 was significantly different from that of the placebo group (<jats:italic>P<\/jats:italic> = 0.03). In the second study of 22 patients treated with 300 mg of T2000 or placebo twice daily for 20 days, statistically significant changes were seen in treated patients compared to baseline, but the ANOVA model did not demonstrate a significant treatment effect of T2000 compared to placebo. When the treated groups from each study are compared, the 800\u2010mg daily group is significantly different from the 600\u2010mg daily group (<jats:italic>P<\/jats:italic> = 0.02). Some treated patients in each study, but no placebo patients, experienced marked improvement. These results support further evaluation of T2000 in the treatment of essential tremor. \u00a9 2006 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21321","type":"journal-article","created":{"date-parts":[[2007,2,2]],"date-time":"2007-02-02T18:22:02Z","timestamp":1170440522000},"page":"723-727","source":"Crossref","is-referenced-by-count":17,"title":["Treatment of essential tremor with the barbiturate t2000 (1,3\u2010dimethoxymethyl\u20105,5\u2010diphenyl\u2010barbituric acid)"],"prefix":"10.1002","volume":"22","author":[{"given":"Calvin","family":"Melmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Moros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Rutman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,4,25]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"438","volume-title":"Movement Disorders","author":"Findley LJ","year":"1987"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.2.221"},{"key":"e_1_2_6_4_2","first-page":"250","article-title":"\u03b2\u2010adrenergic mechanism in essential tremor","volume":"293","author":"Young RR","year":"1975","journal-title":"N Eng J Med"},{"issue":"4","key":"e_1_2_6_5_2","first-page":"S30","article-title":"Pharmacologic treatment of essential tremor","volume":"54","author":"Koller WC","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.48.9.911"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.1.121"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.4.475"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.1.132"},{"key":"e_1_2_6_10_2","first-page":"1784","article-title":"Phenobarbital in essential tremor","volume":"38","author":"Findley LJ","year":"1988","journal-title":"Neurology"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.12.2320"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1975.tb04739.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1979.tb04783.x"},{"issue":"6","key":"e_1_2_6_14_2","first-page":"23","article-title":"Serum and brain levels of 5,5\u2010diphenylbarbituric acid (DPB) after administration of dimethoxymethyl\u2010diphenyl\u2010barbituric acid (T2000) in the rat","volume":"37","author":"Raines A","year":"1996","journal-title":"Epilepsia"},{"key":"e_1_2_6_15_2","unstructured":"WolfHH WhiteHS FranklinMR et al.A preclinical evaluation of the potential antiepileptic utility of ADD 261007. Report from the Anticonvulsant Screening Project of the Epilepsy Branch Neurology Disorders Program National Institute of Neurological Disorders and Stroke. Data on File with Company1988."},{"issue":"4","key":"e_1_2_6_16_2","first-page":"S21","article-title":"Essential tremor: clinical characteristics","volume":"54","author":"Jankovic J","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_6_17_2","first-page":"225","volume-title":"Parkinson's Disease and Movement Disorders","author":"Fahn S","year":"1988"},{"key":"e_1_2_6_18_2","volume-title":"The Design and Analysis of Clinical Experiments","author":"Fleiss JL","year":"1986"},{"key":"e_1_2_6_19_2","unstructured":"SAS Institute Inc.SAS\/STAT User's Guide Version 82."}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21321","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:06:32Z","timestamp":1760958392000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,15]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,4,15]]}},"alternative-id":["10.1002\/mds.21321"],"URL":"https:\/\/doi.org\/10.1002\/mds.21321","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,15]]}}}